# A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

> **NCT06269484** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 73 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
- **DRUG:** Zibotentan + placebo (placebo matching dapagliflozin tablet)
- **DRUG:** Zibotentan + dapagliflozin

## Key facts

- **NCT ID:** NCT06269484
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-15
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269484, "A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06269484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*